1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. (September 2015) - Lüftner, D.; Grischke, E.M.; Fasching, P.; Decker, T.; Schneeweiss, A.; Uleer, C.; Foerster, F.; Wimberger, P.; Kluth-Pepper, B.; Schubert, J.; Bloch, W.; Tesch, H.; et al.